Department of Anesthesiology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, People's Republic of China.
Department of Medical Quality Management, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Drug Des Devel Ther. 2022 Apr 21;16:1131-1142. doi: 10.2147/DDDT.S356284. eCollection 2022.
Being the S-enantiomer of racemic ketamine, esketamine is found to be effective for sedation, analgesia, and treating depression. However, there is no comprehensive bibliometric analysis about esketamine research. In this study, we aimed to determine the scientific output and emerging topics related to esketamine.
Esketamine-related articles and reviews that published between 2000 and 2020 were obtained from the Web of Science Core Collection database, using key word search of "esketamine" "esketamine hydrochloride", "s-ketamine", "S(+)-ketamine", "(S)-ketamine", or "(-)-ketamine". Various bibliographic elements were collected, including the annual number of publications, citation frequency, countries/regions, institutions, authors, journals, and keywords. Two sorts of scientometric software, namely VOS viewer and CiteSpace, were used to conduct bibliometric and knowledge-map analyses.
A total of 683 publications were included in the current study. We found the number of publications in esketamine research field had increased annually since 2016. The United States was the leader in this field, with the highest publications number (162, 23.72%), total citations (3504/9713, 36.08%) and H-index (40). The most productive institution was Chiba University in Japan, and esketamine-related papers were mainly published in the journal . The keyword co-occurrence analysis showed that keywords relevant to depression were the most frequent. Moreover, all identified keywords could be divided into four clusters, with the research focus gradually shifting from cluster of "anesthesia and analgesia detection" to "depression treatment effect.".
The past two decades have shown a marked increase in esketamine research. The United States maintained a top position worldwide, making the most significant contributions in the field of esketamine research. The contributions and collaborations of Asian countries have continuously increased and is a strong area of growth as well as development in recent years. Additionally, the emerging hotspots of esketamine research concentrate on clarifying its depression treatment effect.
埃索凯他（esketamine）作为消旋体氯胺酮的 S-对映体，已被证实具有镇静、镇痛和治疗抑郁症的功效。然而，目前尚无关于埃索凯他研究的全面文献计量分析。本研究旨在确定与埃索凯他相关的研究成果和新兴主题。
从 Web of Science 核心合集数据库中获取了 2000 年至 2020 年间发表的与埃索凯他相关的文章和综述，使用“esketamine”“esketamine hydrochloride”“s-ketamine”“S(+)-ketamine”“(S)-ketamine”或“(-)-ketamine”等关键词进行检索。收集了各种文献计量学元素，包括出版物的年度数量、引用频率、国家/地区、机构、作者、期刊和关键词。使用两种科学计量软件，即 VOS viewer 和 CiteSpace，进行文献计量和知识图谱分析。
本研究共纳入 683 篇出版物。我们发现，自 2016 年以来，埃索凯他研究领域的出版物数量呈逐年增长趋势。美国在该领域处于领先地位，发表的论文数量最多（162 篇，占 23.72%）、总引用次数（3504/9713，占 36.08%）和 H 指数（40）最高。最具生产力的机构是日本的千葉大学，与埃索凯他相关的论文主要发表在《. 》期刊上。关键词共现分析显示，与抑郁症相关的关键词最为频繁。此外，所有确定的关键词可分为四个聚类，研究重点逐渐从“麻醉和镇痛检测”转移到“抑郁症治疗效果”。
在过去的二十年中，埃索凯他的研究明显增多。美国在全球范围内保持领先地位，对埃索凯他研究领域的贡献最大。亚洲国家的贡献和合作不断增加，是近年来的一个强劲增长点和发展领域。此外，埃索凯他研究的新兴热点集中在阐明其治疗抑郁症的效果上。
